A Convenient Protocol for the Synthesis of Fatty Acid Amides

Silje J. R. Johansson; Tonje Johannessen; Christiane F. Ellefsen; Mali S. Ristun; Simen Antonsen; Trond V. Hansen; Yngve Stenstrøm; Jens M. J. Nolsøe

doi:10.1055/s-0037-1611939

Synlett, Table of Contents

Synlett 2019; 30(02): 213-217
DOI: 10.1055/s-0037-1611939

letter

A Convenient Protocol for the Synthesis of Fatty Acid Amides

Authors

Silje J. R. Johansson

^aDepartment of Chemistry, Biology and Food Science, Norwegian University of Life Sciences, P.O. Box 5003, 1432 Ås, Norway Email: jens.mj.nolsoe@nmbu.no
Tonje Johannessen

^aDepartment of Chemistry, Biology and Food Science, Norwegian University of Life Sciences, P.O. Box 5003, 1432 Ås, Norway Email: jens.mj.nolsoe@nmbu.no
Christiane F. Ellefsen

^aDepartment of Chemistry, Biology and Food Science, Norwegian University of Life Sciences, P.O. Box 5003, 1432 Ås, Norway Email: jens.mj.nolsoe@nmbu.no
Mali S. Ristun

^aDepartment of Chemistry, Biology and Food Science, Norwegian University of Life Sciences, P.O. Box 5003, 1432 Ås, Norway Email: jens.mj.nolsoe@nmbu.no
Simen Antonsen

^aDepartment of Chemistry, Biology and Food Science, Norwegian University of Life Sciences, P.O. Box 5003, 1432 Ås, Norway Email: jens.mj.nolsoe@nmbu.no
Trond V. Hansen

^aDepartment of Chemistry, Biology and Food Science, Norwegian University of Life Sciences, P.O. Box 5003, 1432 Ås, Norway Email: jens.mj.nolsoe@nmbu.no

^bDepartment of Pharmaceutical Chemistry, School of Pharmacy, University of Oslo, P.O. Box 1068, Blindern, 0316 Oslo, Norway
Yngve Stenstrøm

^aDepartment of Chemistry, Biology and Food Science, Norwegian University of Life Sciences, P.O. Box 5003, 1432 Ås, Norway Email: jens.mj.nolsoe@nmbu.no
Jens M. J. Nolsøe *

^aDepartment of Chemistry, Biology and Food Science, Norwegian University of Life Sciences, P.O. Box 5003, 1432 Ås, Norway Email: jens.mj.nolsoe@nmbu.no

Abstract

All articles of this category

Abstract

Several classes of biologically occurring fatty acid amides have been reported from mammalian and plant sources. Many amides conjugated with fatty acids of mammalian origin exhibit specific activation of individual receptors. Their potential as pharmacological tools or as lead compounds towards the development of novel therapeutics is of great interest. Hence, access to such amides by a practical, high-yielding and scalable protocol without affecting the geometry or position of sensitive functionalities is needed. A protocol that meets all these requirements involves activation of the corresponding acid with carbonyl diimidazole (CDI) followed by reaction with the desired amine or its hydrochloride. More than fifty compounds have been prepared in generally high yields.

Key words

fatty acid amides - CDI - AM404 - ethanolamide - N-acylethanolamines (NAEs) - N-acyl dopamines (NAPs) - N-acyl amino acids (NAAs) - anandamide

Full Text

References

References and Notes
1 Kuehl Jr FA, Jacob TA, Ganley OH, Ormond RE, Meisinger MA. P. J. Am. Chem. Soc. 1957; 79: 5577

2a Epps DE, Schmid PC, Natarajan V, Schmid HH. O. Biochem. Biophys. Res. Commun. 1979; 90: 628
2b Epps DE, Natarajan V, Schmid PC, Schmid HH. O. Biochim. Biophys. Acta, Lipids Lipid Metab. 1980; 618: 420

3 Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R. Science 1992; 258: 1946
4 Jeffries KA, Dempsey DR, Farrell EK, Anderson RL, Garbade GJ, Gurina TS, Gruhonjic I, Gunderson CA, Merkler DJ. J. Lipid Res. 2016; 57: 781

5a Starowicz K, Nigam S, Di Marzo V. Pharmacol. Ther. 2007; 114: 13
5b Di Marzo V, Bisogno T, De Petrocellis L. Chem. Biol. 2007; 14: 741
5c Liu J, Wang L, Harvey-White J, Huang BX, Kim H.-Y, Luquet S, Palmiter RD, Krystal G, Rai R, Mahadevan A, Razdan RK, Kunos G. Neuropharmacology 2008; 54: 1
5d Schmid HH. O, Berdyshev EV. Prostaglandins, Leukot. Essent. Fatty Acids 2002; 66: 363
5e Sugiura T, Kondo S, Sukagawa A, Tonegawa T, Nakane S, Yamashita A, Ishima Y, Waku K. Eur. J. Biochem. 1996; 240: 53
5f Mechoulam R, Fride E, Di Marzo V. Eur. J. Pharmacol. 1998; 359: 1

6a Patel D, Witt SN. Oxid. Med. Cell. Longevity 2017; 2017: 18
6b Rockenfeller P, Koska M, Pietrocola F, Minois N, Knittelfelder O, Sica V, Franz J, Carmona-Gutierrez D, Kroemer G, Madeo F. Cell Death Differ. 2015; 22: 499
6c Ohno-Shosaku T, Tanimura A, Hashimotodani Y, Kano M. Neuroscientist 2012; 18: 119

7a Coyne L, Lees G, Nicholson RA, Zheng J, Neufield KD. Br. J. Pharmacol. 2002; 135: 1977
7b Huidobro-Toro JP, Harris RA. Proc. Natl. Acad. Sci. U.S.A. 1996; 93: 8078
7c Hedlund PB, Carson MJ, Sutcliffe JG, Thomas EA. Biochem. Pharmacol. 1999; 58: 1807

8a Micale V, Mazzola C, Drago F. Pharmacol. Res. 2007; 56: 382
8b Pillarisetti S, Alexander CW, Khanna I. Drug Discovery Today 2009; 14: 1098

9a Burstein S, Salmonsen R. Bioorg. Med. Chem. 2008; 16: 9644
9b Flygare J, Sander B. Semin. Cancer Biol. 2008; 18: 176

10a Hansen HS, Moesgaard B, Hansen HH, Petersen G. Chem. Phys. Lipids 2000; 108: 135
10b Schmid HH. Chem. Phys. Lipids 2000; 108: 71

11a Coyne L, Lees G, Nicholson RA, Zheng J, Neufield KD. Br. J. Pharmacol. 2002; 135: 1977
11b Huidobro-Toro JP, Harris RA. Proc. Natl. Acad. Sci. U.S.A. 1996; 93: 8078
11c Hedlund PB, Carson MJ, Sutcliffe JG, Thomas EA. Biochem. Pharmacol. 1999; 58: 1807

12 Maccarrone M, Pauselli R, di Rienzo M, Finazzi-Agrò A. Biochem. J. 2002; 366: 137
13 Rodriguez de Fonseca F, Navarro M, Gomez R, Escuredo L, Nava F, Fu J, Murillo-Rodriguez E, Gluffrida A, Lo VermeJ, Gaetani S, Kathurla S, Gall C, Piomell D. Nature 2001; 414: 209
14 Cravatt BF, Prospero-Garcia O, Siuzdak G, Gilula NB, Henriksen SJ, Boger DL, Lerner RA. Science 1995; 268: 1506

15a Ottani A, Leone S, Sandrini M, Ferrari A, Bertolini A. Eur. J. Pharmacol. 2006; 531: 280
15b Deshpande LS, DeLorenzo RJ. NeuroReport 2010; 22: 15

16 Montes D'Oca CD. R, Coelho T, Marinho TG, Hack CR. L, Duarte RD. C, Silva Almeidada P, Montes D'Oca MG. Bioorg. Med. Chem. Lett. 2010; 20: 5255
17 Santos T, Montes D'Oca CD. R., Mata-Santos HA, Fenalti J, Pinto N, Coelho T, Berne ME, Almeida da Silva PE, Montes D'Oca MG, Scaini CJ. Bioorg. Med. Chem. Lett. 2016; 26: 739

18a Schotten C. Ber. Dtsch. Chem. Ges. 1884; 17: 2544
18b Baumann E. Ber. Dtsch. Chem. Ges. 1886; 19: 3218
18c Fischer E, Fourneau E. Ber. Dtsch. Chem. Ges. 1901; 34: 2868
18d Gerhardt C. C. R. Acad. Sci. 1852; 34: 755
18e Bergmann M, Zervas L, Salzmann L, Schleich H. Z. Physiol. Chem. 1934; 224: 17
18f Vaughan Jr JR. J. Am. Chem. Soc. 1951; 73: 3547
18g Boissonnas RA. Helv. Chim. Acta 1951; 34: 874
18h Shendage DM, Froehlich R, Haufe G. Org. Lett. 2004; 6: 3675

19 Sheehan JC, Hess GP. J. Am. Chem. Soc. 1955; 77: 1067

20a El-Faham A, Funosas RS, Prohens R, Albericio F. Chem. Eur. J. 2009; 15: 9404
20b Amblard M, Fehrentz J.-A, Martinez J, Subra G. Mol. Biotechnol. 2006; 33: 239
20c Han S.-Y, Kim Y.-A. Tetrahedron 2004; 60: 2447
20d Dourtoglou V, Ziegler JC, Gross B. Tetrahedron Lett. 1978; 1269
20e Adam S. Bioorg. Med. Chem. Lett. 1992; 2: 571

21 General Procedure for Amide CouplingTo a stirred solution of the fatty acid (1.0 mmol, 1.0 equiv.) in CH₂Cl₂ (5 mL) was added CDI (0.178 g, 1.1 mmol, 1.1 equiv.). After 30 min at room temperature, the amine (1.1 mmol, 1.1 equiv.) was added. After 12 h, CH₂Cl₂ (25 mL) was added, followed by saturated aqueous NH₄Cl. The mixture was acidified to pH 2 by addition of HCl, the organic phase was separated, and the aqueous layer was further extracted with CH₂Cl₂ (3 × 10 mL). The organic phases were combined, dried over Na₂SO₄, filtered, and concentrated in vacuo, to give the amide.Example 1: (5Z,8Z,11Z,14Z,17Z)-N-[(R)-1-phenylethyl]icosa-5,8,11,14,17-pentaenamide (R-28)Starting with EPA (0.302 g, 1.0 mmol, 1.0 equiv.) and (R)-α-methylbenzylamine (0.133 g, 0.14 mL, 1.1 mmol, 1.1 equiv.). Yield 0.376 g, 93%; TLC (hexane/EtOAc 75:25, visualized by UV and KMnO₄ stain): R_f = 0.20; [α]_D ²⁰ +5.2 (c = 0.2, MeOH). ¹H NMR (400 MHz, CDCl₃): δ = 7.49–7.06 (m, 5 H), 5.65 (d, J = 8.2 Hz, 1 H), 5.47–5.27 (m, 10 H), 5.15 (p, J = 7.1 Hz, 1 H), 2.91–2.73 (m, 8 H), 2.18 (dd, J = 8.3, 6.6 Hz, 2 H), 2.15–2.02 (m, 4 H), 1.79–1.67 (m, 2 H), 1.50 (d, J = 6.9 Hz, 3 H), 0.98 (t, J = 7.5 Hz, 3 H). ¹³C NMR (100 MHz, CDCl₃): δ = 171.7, 143.2, 132.0, 129.1, 128.7 (2 × CH), 128.6, 128.5, 128.2, 128.2, 128.1, 128.0, 127.8, 127.3, 126.9, 126.1(2 × CH), 48.6, 36.1, 26.6, 25.6, 25.5, 25.4, 21.6, 20.5, 14.2. IR(ATR): ν_max = 3300, 3014, 2964, 1644, 1544 cm^–1. HRMS (EI⁺): exact mass calcd for C₂₈H₃₉NO [M]⁺ m/z = 405.3032; found: 405.3051.Antipodal S-28Yield 0.403 g, >96%; [α]_D ²⁰ –5.4 (c = 0.3, MeOH).Example 2: (4Z,7Z,10Z,13Z,16Z,19Z)-N-[(R)-1-phenylethyl]-docosa-4,7,10,13,16,19-hexaenamide (R-14)Starting with DHA (0.328 g, 1.0 mmol, 1.0 equiv.) and (R)-α-methylbenzylamine (0.133 g, 0.14 mL, 1.1 mmol, 1.1 equiv.). Yield 0.417 g, >96%; TLC (hexane/EtOAc 75:25, visualized by UV and KMnO₄ stain): R_f = 0.23; [α]_D ²⁰ +6.5 (c = 0.2, MeOH). ¹H NMR (400 MHz, CDCl₃): δ = 7.39–7.21 (m, 5 H), 5.68 (d, J = 7.9 Hz, 1 H), 5.47–5.26 (m, 12 H), 5.15 (p, J = 7.0 Hz, 1 H), 2.91–2.77 (m, 10 H), 2.46–2.38 (m, 2 H), 2.27–2.21 (m, 2 H), 2.13–2.03 (m, 2 H), 1.49 (d, J = 7.0 Hz, 3 H), 0.98 (t, J = 7.5 Hz, 3 H). ¹³C NMR (100 MHz, CDCl₃): δ = 171.2, 143.1, 132.0, 129.3, 128.6 (2 × CH), 128.5, 128.2 (2 × CH), 128.2 (2 × CH), 128.1, 128.0, 128.0, 127.8, 127.3, 127.0, 126.2 (2 × CH), 48.6, 36.5, 25.6, 25.6, 25.6, 25.5, 23.4, 21.7, 20.5, 14.2. IR(ATR): ν_max = 3294, 3014, 2964, 1644, 1544 cm^–1. HRMS (EI⁺): exact mass calcd for C₃₀H₄₁NO [M]⁺ m/z = 431.3188; found: 431.3164.Antipodal S-14Yield 0.430 g, >96%; [α]_D ²⁰ –6.2 (c = 0.2, MeOH).Example 3: (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaen morpholide (12)Starting with EPA (0.302 g, 1.0 mmol, 1.0 equiv.) and morpholine (0.096 g, 0.095 mL, 1.1 mmol, 1.1 equiv.). Yield 0.417 g, >96%; TLC (hexane/EtOAc 40:60, visualized by UV and KMnO₄ stain): R_f = 0.32. ¹H NMR (400 MHz, CDCl₃): δ = 5.45–5.25 (m, 10 H), 3.66 (dd, J = 5.7, 3.9 Hz, 4 H), 3.62 (d, J = 4.9 Hz, 2 H), 3.45 (d, J = 4.9 Hz, 2 H), 2.90–2.75 (m, 8 H), 2.34–2.28 (m, 2 H), 2.18–2.02 (m, 4 H), 1.72 (p, J = 7.5 Hz, 2 H), 0.98 (t, J = 7.5 Hz, 3 H). ¹³C NMR (100 MHz, CDCl₃): δ = 171.5, 132.0, 129.2, 128.7, 128.5, 128.2, 128.2, 128.1, 128.0, 127.8, 126.9, 66.9, 66.6, 45.9, 41.8, 32.3, 26.7, 25.6, 25.6, 25.5, 24.9, 20.5, 14.2. IR (ATR): ν_max = 3009, 2964, 2931, 2863, 1656, 1432 cm^–1. HRMS (EI⁺): exact mass calcd for C₂₄H₃₇NO₂ [M]⁺ m/z = 371.2824; found: 371.2833.
22 Miller MJ. Chem. Rev. 1989; 89: 1563-1579; and references therein

23a Chu CJ, Huang SM, De Petrocellis L, Bisogno T, Ewing SA, Miller JD, Zipkin RE, Daddario N, Appendino G, Di Marzo V, Walker JM. J. Biol. Chem. 2003; 278: 13633
23b Huang SM, Bisogno T, Trevisani M, Al-Hayani A, De Petrocellis L, Fezza F, Tognetto M, Petros TJ, Krey JF, Chu CJ, Miller JD, Davies SN, Geppetti P, Walker JM, Di Marzo V. Proc. Natl. Acad. Sci. U.S.A. 2002; 99: 8400

24a Antonsen SG, Gallantree-Smith H, Gorbitz CH, Hansen TV, Stenstroem YH, Nolsoee JM. J. Molecules 2017; 22: 1720/1-1720/18
24b Gallantree-Smith HC, Antonsen SG, Gorbitz CH, Hansen TV, Nolsoee JM. J, Stenstroem YH. Org. Biomol. Chem. 2016; 14: 8433

25 Kohno M, Hasegawa H, Inoue A, Muraoka M, Miyazaki T, Oka K, Yasukawa M. Biochem. Biophys. Res. Commun. 2006; 347: 827

Supplementary Material

Supporting Information (PDF) (opens in new window)